Literature DB >> 10085065

Chimeric receptors of the human C3a receptor and C5a receptor (CD88).

T Crass1, R S Ames, H M Sarau, M A Tornetta, J J Foley, J Köhl, A Klos, W Bautsch.   

Abstract

Chimeras were generated between the human anaphylatoxin C3a and C5a receptors (C3aR and C5aR, respectively) to define the structural requirements for ligand binding and discrimination. Chimeric receptors were generated by systematically exchanging between the two receptors four receptor modules (the N terminus, transmembrane regions 1 to 4, the second extracellular loop, and transmembrane region 5 to the C terminus). The mutants were transiently expressed in HEK-293 cells (with or without Galpha-16) and analyzed for cell surface expression, binding of C3a and C5a, and functional responsiveness (calcium mobilization) toward C3a, C5a, and a C3a as well as a C5a analogue peptide. The data indicate that in both anaphylatoxin receptors the transmembrane regions and the second extracellular loop act as a functional unit that is disrupted by any reciprocal exchange. N-terminal substitution confirmed the two-binding site model for the human C5aR, in which the receptor N terminus is required for high affinity binding of the native ligand but not a C5a analogue peptide. In contrast, the human C3a receptor did not require the original N terminus for high affinity binding of and activation by C3a, a result that was confirmed by N-terminal deletion mutants. This indicates a completely different binding mode of the anaphylatoxins to their corresponding receptors. The C5a analogue peptide, but not C5a, was an agonist of the C3aR. Replacement of the C3aR N terminus by the C5aR sequence, however, lead to the generation of a true hybrid C3a/C5a receptor, which bound and functionally responded to both ligands, C3a and C5a.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085065     DOI: 10.1074/jbc.274.13.8367

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

Review 2.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 3.  The Role of Complement C3a Receptor in Stroke.

Authors:  Saif Ahmad; Kanchan Bhatia; Adam Kindelin; Andrew F Ducruet
Journal:  Neuromolecular Med       Date:  2019-05-17       Impact factor: 3.843

Review 4.  C4a: An Anaphylatoxin in Name Only.

Authors:  Scott R Barnum
Journal:  J Innate Immun       Date:  2015-02-06       Impact factor: 7.349

5.  The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding.

Authors:  Anne-Marie Scola; Adrian Higginbottom; Lynda J Partridge; Robert C Reid; Trent Woodruff; Stephen M Taylor; David P Fairlie; Peter N Monk
Journal:  J Biol Chem       Date:  2006-12-11       Impact factor: 5.157

Review 6.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

7.  Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans.

Authors:  Claudia Monari; Thomas R Kozel; Francesco Bistoni; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

Review 8.  Function, structure and therapeutic potential of complement C5a receptors.

Authors:  P N Monk; A-M Scola; P Madala; D P Fairlie
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

9.  Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor.

Authors:  M Farzan; C E Schnitzler; N Vasilieva; D Leung; J Kuhn; C Gerard; N P Gerard; H Choe
Journal:  J Exp Med       Date:  2001-05-07       Impact factor: 14.307

10.  Remote ischemic preconditioning (RIPC) modifies the plasma proteome in children undergoing repair of tetralogy of fallot: a randomized controlled trial.

Authors:  Michele Hepponstall; Vera Ignjatovic; Steve Binos; Chantal Attard; Vasiliki Karlaftis; Yves d'Udekem; Paul Monagle; Igor E Konstantinov
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.